US4576693075
© PR Newswire
28.01.2026
INSM
LISTED
NASDAQ
Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress
News Preview
—Abstracts Include the Phase 3 PALM-PAH Study Design, a Presentation of the Previously Disclosed Topline Phase 2b PAH Data, a Functional Respiratory Imaging Analysis from the Phase 2b Study in Pulmonary Arterial Hypertension (PAH), and Pulmonary Vasodilation Data in Rat Models—BRIDGEWATER, N.J., Jan. 28, 2026 /PRNewswire/ -- Insmed Incorporated (N...
Themefolio
Profiler
Peergroup
© PR Newswire
09.01.2026
INSM
LISTED
NASDAQ
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
News Preview
— BRINSUPRI® (brensocatib) Unaudited Total Revenues of Approximately $144.6 Million for First Full Quarter of Launch; Approximately $172.7 Million for Full-Year 2025——ARIKAYCE® (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2025 with Unaudited Global Revenues of Approximately $433.8 Million——Full-Ye...
Themefolio
Profiler
Peergroup
© PR Newswire
02.01.2026
INSM
LISTED
NASDAQ
Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
BRIDGEWATER, N.J., Jan. 2, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the J.P. Morgan 2026 Healthcare Conference in San Fran...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
30.12.2025
INSM
LISTED
NASDAQ
INSM Investors Have Opportunity to Join Insmed Incorporated Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Insmed Incorporated (“Insmed” or “the Company”) (NASDAQ: INSM) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to d...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© PR Newswire
17.12.2025
INSM
LISTED
NASDAQ
Insmed Provides Clinical and Business Update
News Preview
—Phase 2b BiRCh Study of Brensocatib in CRSsNP Did Not Meet Primary or Secondary Efficacy Endpoints; Safety Consistent with Previous Studies; Insmed Discontinues CRSsNP Program——Company Acquires Phase 2 Ready Monoclonal Antibody for Potential Respiratory and Immunological & Inflammatory Indications—BRIDGEWATER, N.J., Dec. 17, 2025 /PRNewswire/...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
INSM
LISTED
NASDAQ
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
BRIDGEWATER, N.J., Dec. 4, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 92 new employees. The awards were granted under t...
Themefolio
Profiler
Peergroup
© PR Newswire
18.11.2025
INSM
LISTED
NASDAQ
European Commission Approves BRINSUPRI® (brensocatib) as the First and Only Treatment To Date Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
News Preview
— Non-Cystic Fibrosis Bronchiectasis (NCFB) Is a Serious, Progressive Lung Disease That Can Lead to Permanent Lung Damagei —
— BRINSUPRI Is a First-in-Disease, First-in-Class DPP1 Inhibitor Targeting Neutrophilic Inflammation —
— BRINSUPRI Was Reviewed Under EMA's Accelerated Assessment Pathway...
Themefolio
Profiler
Peergroup
© PR Newswire
18.11.2025
INSM
LISTED
NASDAQ
European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
News Preview
—
Non-Cystic Fibrosis Bronchiectasis (NCFB) Is a Serious, Progressive Lung Disease That Can Lead to Permanent Lung Damage —
— BRINSUPRI Is a First-in-Disease, First-in-Class DPP1 Inhibitor Targeting Neutrophilic Inflammation —...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
INSM
LISTED
NASDAQ
Insmed To Present at November and December 2025 Investor Conferences
News Preview
BRIDGEWATER, N.J., Nov. 5, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following inves...
Themefolio
Profiler
Peergroup
© PR Newswire
23.10.2025
INSM
LISTED
NASDAQ
Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List
News Preview
—Insmed Leads Science Top Employers List for Fifth Year in a Row—
BRIDGEWATER, N.J., Oct. 23, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of...
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
INSM
LISTED
NASDAQ
CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis
News Preview
— If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis (NCFB) and the First-in-Class DPPI Inhibitor Targeting Neutrophilic Inflammation
— BRINSUPRI Was Reviewed Under CHMP's Accelerated Assessment Pathway as It...
Themefolio
Profiler
Peergroup
© PR Newswire
16.10.2025
INSM
LISTED
NASDAQ
Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025
News Preview
—Data on Structural Lung Changes from a High-Resolution CT Substudy to be Presented as Late-Breaker—
—Additional Analyses Will Highlight Efficacy, Symptom Reduction, and Biomarker Suppression in Patients with Non-Cystic Fibrosis Bronchiectasis—...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
15.10.2025
INSM
LISTED
NASDAQ
Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025
News Preview
BRIDGEWATER, N.J., Oct. 15, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its third-quarter 2025 financ...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
INSM
LISTED
NASDAQ
Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025
News Preview
—Data from Phase 2b Study of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Arterial Hypertension to be Presented at Late-Breaking ALERT Session—
—New Analysis from Phase 3 ASPEN Trial Examines Efficacy and Safety of Brensocatib in Japanese Patients with Non-Cystic Fibrosis Bronchiectasis by Reduction of Exacerbation History— ...
Themefolio
Profiler
Peergroup
© PR Newswire
05.09.2025
INSM
LISTED
NASDAQ
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
BRIDGEWATER, N.J., Sept. 5, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 115 new employees. The awards were granted unde...
Themefolio
Profiler
Peergroup
© PR Newswire
12.08.2025
INSM
LISTED
NASDAQ
FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
News Preview
— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage —
— BRINSUPRI 10 mg and 25 mg Doses Approved for the Treatment of NCFB —
— BRINSUPRI, a First-in-Class DPP1 Inhibitor Targeting Neutrophilic Inflammation, Is Available by Prescription Thr...
Themefolio
Profiler
Peergroup
© PR Newswire
24.07.2025
INSM
LISTED
NASDAQ
Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025
News Preview
BRIDGEWATER, N.J., July 24, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its second-quarter 2025 financial results on Thursday, August 7...
Themefolio
Profiler
Peergroup
© PR Newswire
12.06.2025
INSM
LISTED
NASDAQ
Insmed Announces Pricing of $750 Million Public Offering of Common Stock
News Preview
BRIDGEWATER, N.J., June 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it priced an underwritten public offering of 7,812,500 shares of its common sto...
Themefolio
Profiler
Peergroup
© PR Newswire
11.06.2025
INSM
LISTED
NASDAQ
Insmed Announces Proposed $650 Million Public Offering of Common Stock
News Preview
BRIDGEWATER, N.J., June 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it intends to offer and sell $650 million of shares of its common stock in an und...
Themefolio
Profiler
Peergroup
© PR Newswire
10.06.2025
INSM
LISTED
NASDAQ
Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension
News Preview
–The Study Met Primary and All Secondary Efficacy Endpoints–
Statistically Significant 35% Placebo-Adjusted Reduction from Baseline in Pulmonary Vascular Resistance for the Primary Endpoint (p<0.001) 35.5 Meter Placebo-Adjusted Improvement in Six-Minute Walk Distance for the Secondary Efficacy Endpoint (p=0.003) 60% Placebo-Adjusted Reduction...
Themefolio
Profiler
Peergroup
© PR Newswire
04.06.2025
INSM
LISTED
NASDAQ
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
BRIDGEWATER, N.J., June 4, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 150 new employees. The awards were granted under...
Themefolio
Profiler
Peergroup
© PR Newswire
28.05.2025
INSM
LISTED
NASDAQ
Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference
News Preview
BRIDGEWATER, N.J., May 28, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the 2025 Goldman Sachs Annual Global Healthcare Confe...
Themefolio
Profiler
Peergroup
© PR Newswire
21.05.2025
INSM
LISTED
NASDAQ
Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study
News Preview
— Insmed Presented 11 Abstracts at ATS 2025 from Across Its Respiratory Portfolio, Including Data on ARIKAYCE®, TPIP and Health Economics and Outcomes Research —
BRIDGEWATER, N.J., May 21, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best...
Themefolio
Profiler
Peergroup
© PR Newswire
08.05.2025
INSM
LISTED
NASDAQ
Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update
News Preview
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $92.8 Million for the First Quarter of 2025, Reflecting 23% Growth Over the First Quarter of 2024—
—NDA for Brensocatib in Patients with Bronchiectasis Remains on Track, with a PDUFA Target Action Date of August 12, 2025—
—Phase 2b Study of TPIP in Patients with PAH Completed;...
Themefolio
Profiler
Peergroup
© PR Newswire
29.04.2025
INSM
LISTED
NASDAQ
Insmed To Present at the BofA Securities 2025 Health Care Conference
News Preview
BRIDGEWATER, N.J., April 29, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the BofA Securities 2025 Health Care Conference in...
Themefolio
Profiler
Peergroup
© PR Newswire
24.04.2025
INSM
LISTED
NASDAQ
Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028
News Preview
BRIDGEWATER, N.J., April 24, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it has called all $569.5 million aggregate principal amount of its remaining o...
Themefolio
Profiler
Peergroup
© PR Newswire
23.04.2025
INSM
LISTED
NASDAQ
New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis
News Preview
—Largest Global Clinical Trial Ever Conducted in Bronchiectasis Demonstrates Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Placebo—
—Brensocatib 25 mg is the First Investigational Therapy for Bronchiectasis to Show a Statistically Significant Reduction in the Rate of Lung Function Dec...
Themefolio
Profiler
Peergroup
© PR Newswire
23.04.2025
INSM
LISTED
NASDAQ
Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025
News Preview
BRIDGEWATER, N.J., April 23, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its first-quarter 2025 financial results on Thursday, May 8, 2...
Themefolio
Profiler
Peergroup
© PR Newswire
25.03.2025
INSM
LISTED
NASDAQ
Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference
News Preview
—New Analyses from the Phase 3 ASPEN Study Examining Efficacy and Safety of Brensocatib Across a Variety of Prespecified Subgroups—
—Data from ASPEN Post-hoc Analysis Evaluating Changes in Lung Function in Bronchiectasis Patients Who Did or Did Not Experience Pulmonary Exacerbations in the Trial—
—Data on Health Status Improvements Over Time Foll...
Themefolio
Profiler
Peergroup
© PR Newswire
10.03.2025
INSM
LISTED
NASDAQ
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
BRIDGEWATER, N.J., March 10, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 18 new employees. In accordance with NASDAQ Li...
Themefolio
Profiler
Peergroup
© PR Newswire
24.02.2025
INSM
LISTED
NASDAQ
Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis
News Preview
—FDA Reaffirms Application is Under Priority Review with a PDUFA Target Action Date of August 12, 2025—
BRIDGEWATER, N.J., Feb. 24, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseas...
Themefolio
Profiler
Peergroup
© PR Newswire
20.02.2025
INSM
LISTED
NASDAQ
Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update
News Preview
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $104.4 Million for Fourth-Quarter and $363.7 Million for Full-Year 2024, Reflecting 19% Annual Growth and Exceeding the Upper End of Full-Year 2024 Guidance Range—
—Company Reiterates 2025 Global ARIKAYCE Revenue Guidance of $405 Million to $425 Million, Reflecting Double-Digit...
Themefolio
Profiler
Peergroup
© PR Newswire
11.02.2025
INSM
LISTED
NASDAQ
Insmed To Present at March 2025 Investor Conferences
News Preview
BRIDGEWATER, N.J., Feb. 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences:
45th Annual TD C...
Themefolio
Profiler
Peergroup
© PR Newswire
06.02.2025
INSM
LISTED
NASDAQ
FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025
News Preview
—Brensocatib Would be the First and Only Available Treatment for Bronchiectasis and First DPP1 Inhibitor, if Approved—
BRIDGEWATER, N.J., Feb. 6, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing...
Themefolio
Profiler
Peergroup
© PR Newswire
03.01.2025
INSM
LISTED
NASDAQ
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
BRIDGEWATER, N.J., Jan. 3, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 19 new employees. In accordance with NASDAQ List...
Themefolio
Profiler
Peergroup
© PR Newswire
02.01.2025
INSM
LISTED
NASDAQ
Insmed To Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
BRIDGEWATER, N.J., Jan. 2, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference in...
Themefolio
Profiler
Peergroup
© PR Newswire
02.12.2024
INSM
LISTED
NASDAQ
Insmed To Present at December 2024 Investor Conferences
News Preview
BRIDGEWATER, N.J., Dec. 2, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences:
Evercore ISI Heal...
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2024
INSM
LISTED
NASDAQ
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
BRIDGEWATER, N.J., Nov. 7, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 27 new employees. In accordance with NASDAQ List...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2024
INSM
LISTED
NASDAQ
Insmed To Present at November 2024 Investor Conferences
News Preview
BRIDGEWATER, N.J., Nov. 6, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences:
Guggenheim's Inau...
Themefolio
Profiler
Peergroup
© PR Newswire
31.10.2024
INSM
LISTED
NASDAQ
Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update
News Preview
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $93.4 Million for the Third Quarter of 2024, Reflecting 18% Growth Over the Third Quarter of 2023—
—NDA Submission for Brensocatib in Bronchiectasis Remains on Track for the Fourth Quarter of 2024 with Potential U.S. Launch Still Expected in Mid-2025—
—Expanded U.S. Sales Force...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2024
INSM
LISTED
NASDAQ
Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List
News Preview
—Insmed Leads Science Top Employers List for Fourth Year in a Row—
BRIDGEWATER, N.J., Oct. 24, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it has earned...
Themefolio
Profiler
Peergroup
© PR Newswire
23.10.2024
INSM
LISTED
NASDAQ
Insmed Unites Across Communities Around the World During Third Annual Global Day of Good
News Preview
Company-wide day of service brings together more than 1,000 employees to support over 40 organizations throughout the U.S., Europe, and Japan
BRIDGEWATER, N.J., Oct. 23, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the...
Themefolio
Profiler
Peergroup
© PR Newswire
08.10.2024
INSM
LISTED
NASDAQ
New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results
News Preview
—Data Presented at the CHEST 2024 Annual Meeting—
BRIDGEWATER, N.J., Oct. 8, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today presented positive late-breaking subgroup dat...
Themefolio
Profiler
Peergroup
© PR Newswire
04.10.2024
INSM
LISTED
NASDAQ
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
BRIDGEWATER, N.J., Oct. 4, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 52 new employees. In accordance with NASDAQ List...
Themefolio
Profiler
Peergroup
© PR Newswire
06.09.2024
INSM
LISTED
NASDAQ
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
BRIDGEWATER, N.J., Sept. 6, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 60 new employees. In accordance with NASDAQ Lis...
Themefolio
Profiler
Peergroup
© PR Newswire
08.08.2024
INSM
LISTED
NASDAQ
Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update
News Preview
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $90.3 Million for the Second Quarter of 2024, Reflecting 17% Growth Over the Second Quarter of 2023—
—U.S. Launch Readiness for Brensocatib in Bronchiectasis Remains on Track with NDA Submission Expected in the Fourth Quarter of 2024—
—Primary Endpoint for ENCORE Study of ARIKA...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
